3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

→ Chi­na’s 3SBio has li­censed rights to three im­muno-on­col­o­gy as­sets dis­cov­ered by Verseau Ther­a­peu­tics. Boston-based Verseau has a plat­form built on what it calls macrophage check­point mod­u­la­tors — mon­o­clon­al an­ti­bod­ies that reg­u­late how in­flam­ma­to­ry or tolero­genic macrophages are. In ad­di­tion to tak­ing on the de­vel­op­ment, man­u­fac­tur­ing and com­mer­cial­iza­tion of the MCMs gen­er­at­ed in the pact, 3SBio is al­so par­tic­i­pat­ing in Verseau’s Se­ries B with $15 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER